The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
General Updates | Updates to the ESMO CLL clinical practice guidelines: implications for relapsed disease
In this discussion, Arnon Kater, MD, PhD, University of Amsterdam, Amsterdam, Netherlands, and Paolo Ghia, MD, Vita-Salute San Raffaele University, Milan, Italy, provide key insights into the management of relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL), guided by the latest ESMO clinical practice recommendations. They explore treatment strategies at first relapse and for double-refractory patients, including fixed-duration combinations and the emerging role of the non-covalent BTK inhibitor, pirtobrutinib. This discussion took place virtually.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
